Ligand Pharmaceuticals (LGND) Interest & Investment Income (2010 - 2026)
Ligand Pharmaceuticals recorded quarterly Interest & Investment Income of $6.7 million in Q1 2026, up 4.1% quarter-over-quarter from $6.4 million in Q4 2025, and up 275.78% year-over-year from $1.8 million in Q1 2025.
Ligand Pharmaceuticals' Interest & Investment Income history runs 13 years deep, the most recent figure standing at $6.7 million for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 275.78% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $18.5 million (up 137.55% YoY), while the FY2025 annual figure was $13.7 million, up 69.57% from the prior year.
- Interest & Investment Income came in at $6.7 million for Q1 2026 at Ligand Pharmaceuticals, up from $6.4 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $6.7 million in Q1 2026 to a low of $134000.0 in Q1 2022.
- A 5-year average of $2.2 million and a median of $1.8 million in 2025 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income tumbled 54.73% in 2022 and jumped 970.9% in 2023, its largest moves.
- Ligand Pharmaceuticals' Interest & Investment Income stood at $1.0 million in 2022, then soared by 65.49% to $1.7 million in 2023, then advanced by 14.06% to $1.9 million in 2024, then jumped by 231.07% to $6.4 million in 2025, then climbed by 4.1% to $6.7 million in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $6.7 million, $6.4 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Ligand Pharmaceuticals | 4.61 Bn | 3.83 Bn | 48.45 Mn | 6.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.66 Mn |
| Dec 31, 2025 | 6.39 Mn |
| Sep 30, 2025 | 3.87 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Mar 31, 2025 | 1.77 Mn |
| Dec 31, 2024 | 1.93 Mn |
| Sep 30, 2024 | 1.35 Mn |
| Jun 30, 2024 | 2.76 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Dec 31, 2023 | 1.69 Mn |
| Sep 30, 2023 | 2.26 Mn |
| Jun 30, 2023 | 2.32 Mn |
| Mar 31, 2023 | 1.44 Mn |
| Dec 31, 2022 | 1.02 Mn |
| Sep 30, 2022 | 591,000.00 |
| Jun 30, 2022 | 298,000.00 |
| Mar 31, 2022 | 134,000.00 |
| Dec 31, 2021 | 188,000.00 |
| Sep 30, 2021 | 169,000.00 |
| Jun 30, 2021 | 233,000.00 |
| Mar 31, 2021 | 296,000.00 |
| Dec 31, 2020 | 388,000.00 |
| Sep 30, 2020 | 991,000.00 |
| Jun 30, 2020 | 1.97 Mn |
| Mar 31, 2020 | 4.73 Mn |
| Dec 31, 2019 | 5.84 Mn |
| Sep 30, 2019 | 7.40 Mn |
| Jun 30, 2019 | 9.29 Mn |
| Mar 31, 2019 | 5.91 Mn |
| Dec 31, 2018 | 4.89 Mn |
| Sep 30, 2018 | 5.47 Mn |
| Jun 30, 2018 | 2.76 Mn |
| Mar 31, 2018 | 875,000.00 |
| Dec 31, 2017 | 657,000.00 |
| Sep 30, 2017 | 564,000.00 |
| Jun 30, 2017 | 481,000.00 |
| Mar 31, 2012 | 17,000.00 |
| Sep 30, 2011 | 1,000.00 |
| Mar 31, 2011 | 37,000.00 |
| Dec 31, 2010 | 53,000.00 |
| Sep 30, 2010 | 59,000.00 |
| Jun 30, 2010 | 118,000.00 |